MetaCap

Benitec Biopharma (BNTC) vs Emergent BioSolutions (EBS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Benitec Biopharma (BNTC) has outperformed Emergent BioSolutions (EBS) over the past year, losing 40.3% versus a loss of 49.7%. Over five years, BNTC leads with a -85.7% price change compared with -88.6% for EBS. Benitec Biopharma is the larger company by market cap ($285.9 million vs $259.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTC-40.31%EBS-49.70%
+43%-9%-60%
Nov 21, 20251 yearNov 20, 2026
BNTC-85.45%EBS-87.40%
+37%-33%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTC versus EBS key metrics
MetricBNTCEBS
Share price$7.92$5.05
Market cap$285.88M$259.65M
1-day change-2.76%-1.94%
YTD return-41.24%-59.14%
1-year return-40.31%-49.70%
5-year return-85.67%-88.58%
Forward P/E—4.83
EPS (TTM)$-1.02$-5.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$742.90M
Revenue growth (YoY)—-28.81%
Net income (latest FY)$-45.55M$52.60M
Gross margin—56.09%
Operating margin—13.47%
Net margin—7.08%
52-week high$14.39$14.06
52-week low$7.72$4.36
Distance from 52-week high-45.00%-64.08%
Analyst consensusstrong_buynone
Avg. price target upside+200.06%+98.02%
Average volume174.01K1.11M
Shares outstanding36.12M51.42M
Employees24900
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

About Emergent BioSolutions

EBS stock →

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees

BNTC vs EBS FAQ

Which is bigger, Benitec Biopharma or Emergent BioSolutions?

Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $259.65M for Emergent BioSolutions (EBS).

Which stock has performed better over the past year, BNTC or EBS?

BNTC returned -40.31% over the past 12 months, compared with -49.70% for EBS (price return, excluding dividends). Past performance does not predict future results.

Are Benitec Biopharma and Emergent BioSolutions in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons